Boule Diagnostics AB 2023 AR2
The report highlights Boule Diagnostics AB's financial and operational performance for 2023, showcasing a 4.2% increase in net sales to SEK 571.3 million and an improved gross margin of 43.7%. Key achievements during the year included the successful launch of the H50V veterinary 5-part hematology system in Europe and the establishment of a licensed instrument manufacturing agreement in India to meet local procurement requirements. On the sustainability front, the company focused on reducing transportation emissions, which represent 91% of its estimated CO2e emissions in Sweden, and ensured that 100% of its critical suppliers and distributors signed its Code of Conduct.
Company: Boule Diagnostics AB
Sector: Health Care
Country: Sweden
Year: 2023
Type: AR2
Pages: 96
Back to company
Boule Diagnostics AB
Annual Report
The report highlights Boule Diagnostics AB's financial and operational performance for 2023, showcasing a 4.2% increase in net sales to SEK 571.3 million and an improved gross margin of 43.7%. Key achievements during the year included the successful launch of the H50V veterinary 5-part hematology system in Europe and the establishment of a licensed instrument manufacturing agreement in India to meet local procurement requirements. On the sustainability front, the company focused on reducing transportation emissions, which represent 91% of its estimated CO2e emissions in Sweden, and ensured that 100% of its critical suppliers and distributors signed its Code of Conduct.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees